1. Home
  2. GKOS vs GRFS Comparison

GKOS vs GRFS Comparison

Compare GKOS & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • GRFS
  • Stock Information
  • Founded
  • GKOS 1998
  • GRFS 1940
  • Country
  • GKOS United States
  • GRFS Spain
  • Employees
  • GKOS N/A
  • GRFS N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • GRFS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GKOS Health Care
  • GRFS Health Care
  • Exchange
  • GKOS Nasdaq
  • GRFS Nasdaq
  • Market Cap
  • GKOS 5.8B
  • GRFS 6.2B
  • IPO Year
  • GKOS 2015
  • GRFS 2006
  • Fundamental
  • Price
  • GKOS $94.32
  • GRFS $10.10
  • Analyst Decision
  • GKOS Strong Buy
  • GRFS Hold
  • Analyst Count
  • GKOS 12
  • GRFS 1
  • Target Price
  • GKOS $134.67
  • GRFS $10.30
  • AVG Volume (30 Days)
  • GKOS 869.3K
  • GRFS 1.1M
  • Earning Date
  • GKOS 07-30-2025
  • GRFS 01-01-0001
  • Dividend Yield
  • GKOS N/A
  • GRFS N/A
  • EPS Growth
  • GKOS N/A
  • GRFS N/A
  • EPS
  • GKOS N/A
  • GRFS 0.31
  • Revenue
  • GKOS $404,523,000.00
  • GRFS $7,968,532,207.00
  • Revenue This Year
  • GKOS $27.88
  • GRFS $7.14
  • Revenue Next Year
  • GKOS $27.60
  • GRFS $7.16
  • P/E Ratio
  • GKOS N/A
  • GRFS $41.40
  • Revenue Growth
  • GKOS 23.92
  • GRFS 10.76
  • 52 Week Low
  • GKOS $77.10
  • GRFS $6.19
  • 52 Week High
  • GKOS $163.71
  • GRFS $10.30
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 37.61
  • GRFS 67.23
  • Support Level
  • GKOS $92.42
  • GRFS $9.66
  • Resistance Level
  • GKOS $98.21
  • GRFS $10.30
  • Average True Range (ATR)
  • GKOS 2.85
  • GRFS 0.26
  • MACD
  • GKOS -1.10
  • GRFS 0.00
  • Stochastic Oscillator
  • GKOS 13.19
  • GRFS 85.19

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: